Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The type 1 insulin-like growth factor receptor (IGF1R) is overexpressed by malignant melanomas compared with benign naevi, and mediates proliferation, motility and protection from apoptosis. However, the utility of IGF1R targeting as anti-cancer therapy may be limited by activating mutations in downstream signaling intermediates. We previously showed that IGF1R knockdown blocked survival of prostate cancer cells in which Akt activation was deregulated by PTEN loss. The current study investigated effects of IGF1R targeting in cells harboring activating RAS-RAF mutations, found in 70-80% of human melanomas. We assembled a panel of eight human melanoma cell lines: two expressing wild-type (WT) B-RAF and N-RAS, two with activating N-RAS mutations and four harboring V600E B-RAF. We also generated isogenic cell populations overexpressing WT or V600E B-RAF. Cells expressing V600E B-RAF were relatively resistant to apoptosis. However, IGF1R gene silencing was capable of inducing significant inhibition of survival, enhancement of apoptosis, and approximately two-fold sensitization to cisplatin and temozolomide. These effects were independent of mutation status and were associated with reduced activation of Akt and also, unexpectedly, of ERKs. These results support development of IGF1R targeting as therapy for melanoma, regardless of the presence of activating mutations in the RAS-RAF pathway.

Original publication

DOI

10.1038/sj.onc.1209674

Type

Journal article

Journal

Oncogene

Publication Date

26/10/2006

Volume

25

Pages

6574 - 6581

Keywords

Antineoplastic Agents, Cell Survival, Drug Resistance, Neoplasm, Extracellular Signal-Regulated MAP Kinases, Gene Silencing, Humans, Melanocytes, Melanoma, Point Mutation, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins c-akt, Proto-Oncogene Proteins p21(ras), RNA, Small Interfering, Receptor, IGF Type 1, Signal Transduction, Skin Neoplasms, Transfection, Tumor Cells, Cultured